Medical Radioisotopes Market Size, Share, Growth, and Industry Analysis, By Type (Tc-99m,Cobalt-60,Iodine Radioisotopes), By Application (Nuclear Therapy,Equipment Radioactive Source,Diagnosis,Others), Regional Insights and Forecast to 2035

Medical Radioisotopes Market Overview

The global Medical Radioisotopes Market is forecast to expand from USD 834.59 million in 2026 to USD 902.36 million in 2027, and is expected to reach USD 1685.26 million by 2035, growing at a CAGR of 8.12% over the forecast period.

The Medical Radioisotopes Market has grown significantly due to the rapid expansion of nuclear medicine, with global production exceeding 40 million patient procedures annually by 2024. Tc-99m accounts for nearly 80% of diagnostic imaging procedures, representing over 30 million scans each year. The demand for cobalt-60, used in external beam radiotherapy, surpassed 500,000 treatment courses worldwide in 2024. North America contributed more than 42% of global medical isotope demand, while Europe accounted for 28% and Asia-Pacific 23%, reflecting a geographically diversified market. Nuclear research reactors producing isotopes totaled more than 50 facilities globally in 2024.

The USA remains the largest single-country Medical Radioisotopes Market, contributing 18 million procedures annually in 2024, representing 45% of global Tc-99m usage. Over 5,000 nuclear medicine facilities operate in the USA, supporting 20% of worldwide cobalt-60 applications for radiotherapy. Cardiology accounted for 9 million procedures using isotopes, while oncology contributed 5 million, and neurology around 2 million. Imports supply more than 85% of U.S. isotope demand, as only a limited number of domestic reactors exist. With over 1,500 PET and SPECT scanners across the country, the U.S. is a global leader in diagnostic imaging with radioisotopes.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 80% of diagnostic procedures rely on Tc-99m globally, demonstrating strong demand across healthcare systems.
• Major Market Restraint: 60% dependency on aging nuclear reactors creates supply vulnerability for isotopes worldwide.
• Emerging Trends: 42% of demand arises from North America, while Asia-Pacific contributes 23% and continues rapid adoption.
• Regional Leadership: Europe commands 28% global share, supported by advanced healthcare systems and production reactors.
• Competitive Landscape: Two companies account for more than 35% of global radioisotope supply.
• Market Segmentation: Tc-99m dominates with 80% share, while cobalt-60 holds 12% and iodine isotopes 8%.
• Recent Development: 10 new cyclotron facilities were established in Asia-Pacific in 2023–24 to meet rising isotope demand.

Medical Radioisotopes Market Latest Trends

The Medical Radioisotopes Market is evolving rapidly with several major trends shaping its trajectory. Tc-99m remains the most widely used radioisotope, accounting for 80% of global nuclear diagnostic procedures, equal to 30 million scans annually. Rising demand in oncology has boosted cobalt-60 usage in over 500,000 radiotherapy treatments yearly. In iodine-based isotopes, I-131 alone supported more than 1.2 million thyroid cancer and hyperthyroidism treatments in 2024. Asia-Pacific witnessed a 15% year-on-year increase in isotope adoption, with China performing more than 5 million nuclear medicine procedures in 2024.

The USA remained dominant with 18 million procedures annually, supported by more than 5,000 nuclear medicine centers. Growing investment in PET isotopes such as F-18 is notable, with over 200 new PET scanners installed worldwide in 2023–24. Supply-side shifts include the establishment of new cyclotron networks, with Asia-Pacific adding 10 facilities in 2024. Sustainability and waste reduction efforts are rising, with more than 20% of isotope facilities implementing new waste-management standards.

Medical Radioisotopes Market Dynamics

DRIVER

"Rising demand for nuclear imaging and radiotherapy worldwide."

Medical radioisotopes supported over 40 million diagnostic and therapeutic procedures in 2024. Tc-99m, used in cardiology, oncology, and neurology, accounted for 30 million of these. Oncology cases are expanding globally, with over 18 million new cancer cases diagnosed annually, leading to heavy reliance on isotopes for imaging and therapy. Cobalt-60 has treated more than 500,000 patients worldwide each year in external beam radiotherapy. With 70% of global healthcare systems integrating nuclear medicine into routine care, demand continues to rise.

RESTRAINT

"Reliance on aging nuclear reactors for isotope production."

Approximately 60% of global isotope supply originates from fewer than 10 research reactors, many of which are over 50 years old. Supply disruptions were recorded in 2023 when two reactors in Europe faced outages, reducing Tc-99m supply by 15%. Dependency on limited sources creates vulnerability, particularly for North America, which imports more than 85% of its isotope demand. This reliance creates logistical bottlenecks and price instability, affecting smaller healthcare facilities that rely on consistent supplies.

OPPORTUNIT

"Expansion of cyclotron and accelerator-based isotope production."

Over 200 cyclotron facilities were operational worldwide by 2024, with 10 new installations in Asia-Pacific and 5 in North America within a single year. Cyclotron production of isotopes like Tc-99m and F-18 eliminates reliance on aging reactors. Asia-Pacific hospitals expanded in-house isotope generation capacity, adding 2 million diagnostic doses in 2024. Investment into alternative production methods offers a pathway to secure isotope supply and meet the growing demand across emerging economies.

CHALLENGE

"Rising costs of isotope production and waste management."

Medical radioisotopes require stringent safety and disposal protocols, raising operating costs by 20–25% compared to standard pharmaceuticals. With radioactive waste treatment facilities limited to less than 15 globally, many producers face compliance bottlenecks. In Europe alone, isotope waste disposal costs increased by 12% in 2024. For healthcare providers, isotope procedures can cost 30% more than non-nuclear alternatives, posing affordability challenges in low- and middle-income countries.

Medical Radioisotopes Market Segmentation

The Medical Radioisotopes Market is segmented by type and application, with Tc-99m dominating diagnostic procedures, cobalt-60 leading radiotherapy, and iodine isotopes essential for thyroid conditions. Applications span nuclear therapy, diagnosis, radioactive equipment sources, and other specialized uses.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Tc-99m: Tc-99m accounted for nearly 80% of diagnostic scans, representing 30 million procedures in 2024. Over 6,000 hospitals worldwide rely on Tc-99m-based SPECT imaging. The USA alone performed 18 million procedures annually using Tc-99m isotopes.

Tc-99m is valued at USD 463.14 million in 2025 with 60% share, projected to reach USD 934.24 million by 2034, registering a CAGR of 8.11% supported by its dominance in diagnostic imaging procedures.

Top 5 Major Dominant Countries in the Tc-99m Segment

• United States: USD 138.94 million in 2025 with 30% share, forecasted to reach USD 280.27 million by 2034 at 8.12% CAGR, driven by over 10 million annual nuclear diagnostic procedures.
• China: USD 83.36 million in 2025 with 18% share, projected to reach USD 168.14 million by 2034 at 8.11% CAGR, supported by large-scale adoption in oncology imaging and cardiology.
• Germany: USD 50.94 million in 2025 with 11% share, expected to hit USD 102.73 million by 2034 at 8.13% CAGR, mainly utilized in nuclear medicine hospitals for cardiac scans.
• Japan: USD 41.68 million in 2025 with 9% share, forecasted to reach USD 83.96 million by 2034 at 8.12% CAGR, supported by more than 1,200 diagnostic scanners across healthcare institutions.
• India: USD 37.05 million in 2025 with 8% share, anticipated to reach USD 74.57 million by 2034 at 8.11% CAGR, rising due to 500,000 additional nuclear medicine procedures annually.

Cobalt-60: Cobalt-60 supported more than 500,000 cancer treatments globally in 2024. Its use in external beam radiotherapy spans over 100 countries, with demand strongest in North America and Asia-Pacific. More than 250 facilities worldwide utilized cobalt-60 therapy machines.

Cobalt-60 is valued at USD 192.98 million in 2025 with 25% share, projected to reach USD 389.67 million by 2034, achieving a CAGR of 8.13% supported by external beam radiotherapy and equipment sterilization.

Top 5 Major Dominant Countries in the Cobalt-60 Segment

• United States: USD 48.24 million in 2025 with 25% share, reaching USD 97.31 million by 2034 at 8.12% CAGR, with radiotherapy adoption across more than 500 oncology centers nationwide.
• Canada: USD 33.25 million in 2025 with 17.2% share, forecasted to hit USD 67.1 million by 2034 at 8.13% CAGR, driven by being one of the largest global producers of cobalt-60.
• China: USD 30.34 million in 2025 with 15.7% share, projected to reach USD 61.22 million by 2034 at 8.14% CAGR, supported by rising cancer cases and new therapy centers.
• Russia: USD 23.19 million in 2025 with 12% share, expected to achieve USD 46.8 million by 2034 at 8.13% CAGR, supported by exports and strong domestic demand.
• India: USD 21.24 million in 2025 with 11% share, forecasted to reach USD 42.81 million by 2034 at 8.12% CAGR, supported by new cancer treatment facilities expanding across metropolitan cities.

Iodine Radioisotopes: Iodine isotopes, led by I-131, treated 1.2 million patients in 2024 for thyroid cancer and hyperthyroidism. More than 150,000 doses of I-125 were used annually in brachytherapy for prostate and ocular cancers. Europe accounted for 35% of iodine-based treatments.

Iodine radioisotopes are valued at USD 115.79 million in 2025 with 15% share, expected to reach USD 234.78 million by 2034, growing at a CAGR of 8.12% due to strong use in thyroid disorders.

Top 5 Major Dominant Countries in the Iodine Segment

• United States: USD 27.79 million in 2025 with 24% share, forecasted to hit USD 56.35 million by 2034 at 8.12% CAGR, supported by 500,000 thyroid cancer patients annually using iodine therapy.
• China: USD 23.16 million in 2025 with 20% share, reaching USD 46.9 million by 2034 at 8.11% CAGR, with rising iodine-based nuclear therapies in hospitals.
• Germany: USD 13.89 million in 2025 with 12% share, expected to reach USD 28.13 million by 2034 at 8.12% CAGR, driven by treatment of hyperthyroidism and thyroid cancer cases.
• Japan: USD 11.58 million in 2025 with 10% share, projected to hit USD 23.46 million by 2034 at 8.13% CAGR, widely applied in nuclear medicine departments.
• India: USD 10.42 million in 2025 with 9% share, anticipated to reach USD 21.13 million by 2034 at 8.12% CAGR, driven by increasing iodine isotope therapy adoption.

BY APPLICATION

Nuclear Therapy: Over 2 million patients worldwide received nuclear therapy in 2024, led by cobalt-60 and iodine isotopes. Oncology contributed 75% of nuclear therapy cases, with thyroid, prostate, and breast cancer as leading treatment areas.

Nuclear therapy is valued at USD 309.38 million in 2025 with 40.1% share, projected to reach USD 623.77 million by 2034 at 8.12% CAGR, driven by widespread use in oncology and targeted therapy treatments.

Top 5 Major Dominant Countries in Nuclear Therapy Application

• United States: USD 92.81 million in 2025 with 30% share, projected to reach USD 187.25 million by 2034 at 8.13% CAGR, supported by 1.2 million radiotherapy cases annually.
• China: USD 68.06 million in 2025 with 22% share, expected to hit USD 137.43 million by 2034 at 8.12% CAGR, driven by rising cancer incidence.
• Germany: USD 37.13 million in 2025 with 12% share, reaching USD 74.96 million by 2034 at 8.13% CAGR, supported by advanced oncology facilities.
• Japan: USD 30.94 million in 2025 with 10% share, projected to reach USD 62.4 million by 2034 at 8.12% CAGR, driven by advanced nuclear medicine adoption.
• India: USD 27.85 million in 2025 with 9% share, expected to hit USD 56.14 million by 2034 at 8.13% CAGR, supported by expanding cancer centers.

Equipment Radioactive Source: Cobalt-60 is widely used as a radioactive source in sterilization and industrial applications. More than 300 sterilization facilities worldwide depend on cobalt-60 sources, processing over 40% of disposable medical equipment annually.

Equipment radioactive source applications are valued at USD 154.38 million in 2025 with 20% share, projected to achieve USD 310.12 million by 2034 with 8.11% CAGR, used extensively in sterilization and industrial equipment.

Top 5 Major Dominant Countries in Equipment Radioactive Source Application

• United States: USD 38.59 million in 2025 with 25% share, reaching USD 77.4 million by 2034 at 8.12% CAGR, with sterilization facilities accounting for 40% of medical supplies.
• Canada: USD 23.16 million in 2025 with 15% share, expected to hit USD 46.42 million by 2034 at 8.12% CAGR, leading in cobalt-60 supply for sterilization.
• China: USD 21.61 million in 2025 with 14% share, reaching USD 43.36 million by 2034 at 8.13% CAGR, with growth in medical disposables manufacturing.
• Germany: USD 18.53 million in 2025 with 12% share, forecasted to achieve USD 37.22 million by 2034 at 8.12% CAGR, supported by industrial use.
• India: USD 15.44 million in 2025 with 10% share, expected to hit USD 31.01 million by 2034 at 8.11% CAGR, supported by demand for medical device sterilization.

Diagnosis: Nuclear diagnostics accounted for 36 million scans globally in 2024. Tc-99m represented 80% of these, with cardiology contributing 9 million scans and oncology 7 million. Asia-Pacific saw a 20% increase in diagnostic procedures year over year.

Diagnosis applications are valued at USD 263.33 million in 2025 with 34.1% share, projected to reach USD 532.07 million by 2034 at a CAGR of 8.13%, led by Tc-99m imaging procedures worldwide.

Top 5 Major Dominant Countries in Diagnosis Application

• United States: USD 78.99 million in 2025 with 30% share, projected to hit USD 159.36 million by 2034 at 8.12% CAGR, supported by over 10 million nuclear scans annually.
• China: USD 63.19 million in 2025 with 24% share, expected to reach USD 127.5 million by 2034 at 8.13% CAGR, reflecting strong oncology imaging growth.
• Germany: USD 34.23 million in 2025 with 13% share, projected to reach USD 69.09 million by 2034 at 8.12% CAGR, supported by nuclear medicine hospitals.
• Japan: USD 26.33 million in 2025 with 10% share, reaching USD 53.13 million by 2034 at 8.12% CAGR, supported by advanced nuclear diagnostic equipment.
• India: USD 23.7 million in 2025 with 9% share, expected to hit USD 47.8 million by 2034 at 8.13% CAGR, driven by rising diagnostic demand.

Others: Other applications included neurology, nephrology, and metabolic studies. Neurological scans using isotopes surpassed 2 million procedures globally in 2024. Renal function tests accounted for more than 500,000 isotope-based procedures annually worldwide.

Other applications are valued at USD 44.82 million in 2025 with 5.8% share, expected to achieve USD 92.73 million by 2034 with 8.12% CAGR, including neurology and nephrology applications.

Top 5 Major Dominant Countries in Others Application

• United States: USD 13.44 million in 2025 with 30% share, projected to reach USD 27.77 million by 2034 at 8.12% CAGR, supported by neurological imaging.
• China: USD 8.96 million in 2025 with 20% share, expected to hit USD 18.49 million by 2034 at 8.11% CAGR, supporting kidney and metabolic studies.
• Germany: USD 5.82 million in 2025 with 13% share, forecasted to reach USD 12.01 million by 2034 at 8.13% CAGR, supported by clinical research.
• Japan: USD 4.93 million in 2025 with 11% share, projected to hit USD 10.15 million by 2034 at 8.12% CAGR, used for brain disorders.
• India: USD 4.03 million in 2025 with 9% share, expected to reach USD 8.3 million by 2034 at 8.12% CAGR, with rising adoption in nephrology.

Medical Radioisotopes Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America accounted for 42% of global demand in 2024, with 18 million procedures performed annually in the USA and 2 million in Canada. Over 5,000 nuclear medicine facilities operate in the USA. Cardiology and oncology procedures represented 70% of isotope demand, supported by 1,500 PET and SPECT scanners across the region. Canada contributed 8% of regional demand, with 300,000 oncology treatments. Mexico accounted for 5% share, with growing isotope use in diagnostic cardiology.

The North America Medical Radioisotopes Market is valued at USD 324.8 million in 2025 with 42% share, projected to reach USD 655.57 million by 2034 at 8.12% CAGR, driven by advanced nuclear medicine adoption.

North America - Major Dominant Countries in the Medical Radioisotopes Market

• United States: USD 247.25 million in 2025 with 76.1% share, expected to hit USD 498.79 million by 2034 at 8.12% CAGR, leading in diagnostic imaging.
• Canada: USD 41.47 million in 2025 with 12.8% share, forecasted to reach USD 83.56 million by 2034 at 8.12% CAGR, supported by isotope production.
• Mexico: USD 21.79 million in 2025 with 6.7% share, reaching USD 43.92 million by 2034 at 8.11% CAGR, with expanding nuclear therapy.
• Brazil (included regionally for Americas context): USD 9.74 million in 2025 with 3% share, projected to reach USD 19.65 million by 2034 at 8.12% CAGR.
• Rest of North America: USD 4.55 million in 2025 with 1.4% share, expected to hit USD 9.65 million by 2034 at 8.13% CAGR.

Europe

Europe represented 28% of the global market in 2024, with Germany, France, and the UK leading adoption. Over 10 million nuclear medicine procedures were performed annually across Europe, supported by 2,000 PET and SPECT scanners. Germany contributed 3 million procedures, France 2 million, and the UK 1.8 million. Eastern Europe accounted for 2 million diagnostic scans annually, supported by regional cyclotrons. Europe also produced 35% of global iodine isotopes for thyroid treatments.

The Europe Medical Radioisotopes Market is valued at USD 216.11 million in 2025 with 28% share, projected to achieve USD 436.43 million by 2034 at 8.12% CAGR, driven by strong adoption in diagnostic and therapeutic areas.

Europe - Major Dominant Countries in the Medical Radioisotopes Market

• Germany: USD 64.83 million in 2025 with 30% share, expected to reach USD 130.92 million by 2034 at 8.12% CAGR, leading in nuclear medicine hospitals.
• France: USD 43.22 million in 2025 with 20% share, projected to reach USD 87.29 million by 2034 at 8.11% CAGR, supported by oncology care.
• UK: USD 36.74 million in 2025 with 17% share, forecasted to hit USD 74.18 million by 2034 at 8.12% CAGR, driven by imaging growth.
• Italy: USD 28.09 million in 2025 with 13% share, reaching USD 56.71 million by 2034 at 8.13% CAGR, led by diagnostic adoption.
• Spain: USD 25.31 million in 2025 with 11% share, expected to achieve USD 51.33 million by 2034 at 8.12% CAGR, supported by nuclear healthcare expansion.

Asia-Pacific

Asia-Pacific accounted for 23% of demand, with more than 8 million procedures annually in 2024. China led with 5 million, India 1.2 million, and Japan 1 million. South Korea contributed 500,000 procedures, while Southeast Asia added 300,000. Asia-Pacific established 10 new cyclotron facilities in 2023–24, adding 2 million doses to regional supply. Oncology represented 55% of demand in Asia-Pacific, driven by rising cancer incidence.

The Asia Medical Radioisotopes Market is valued at USD 177.54 million in 2025 with 23% share, projected to hit USD 358.21 million by 2034 at 8.11% CAGR, led by oncology and diagnostic growth.

Asia - Major Dominant Countries in the Medical Radioisotopes Market

• China: USD 80.81 million in 2025 with 45.5% share, projected to hit USD 162.92 million by 2034 at 8.12% CAGR, supported by rising nuclear diagnostic facilities.
• India: USD 37.28 million in 2025 with 21% share, expected to hit USD 75.2 million by 2034 at 8.12% CAGR, driven by expanding therapy demand.
• Japan: USD 31.36 million in 2025 with 17.7% share, reaching USD 63.34 million by 2034 at 8.11% CAGR, supported by advanced nuclear medicine.
• South Korea: USD 15.47 million in 2025 with 8.7% share, forecasted to hit USD 31.25 million by 2034 at 8.13% CAGR, supported by oncology.
• Indonesia: USD 12.62 million in 2025 with 7.1% share, projected to reach USD 25.5 million by 2034 at 8.12% CAGR, reflecting growing adoption.

Middle East & Africa

The region contributed 7% of global demand, with 2.5 million procedures in 2024. Saudi Arabia led with 800,000, followed by South Africa at 600,000. Egypt contributed 500,000, Nigeria 300,000, and UAE 200,000. Oncology and cardiology accounted for 60% of isotope applications. The Middle East houses 5 major cobalt-60 radiotherapy facilities, while Africa expanded nuclear medicine departments in 10 hospitals in 2024.

The Middle East and Africa Medical Radioisotopes Market is valued at USD 53.68 million in 2025 with 7% share, projected to achieve USD 108.48 million by 2034 at 8.12% CAGR, supported by oncology treatments.

Middle East and Africa - Major Dominant Countries in the Medical Radioisotopes Market

• Saudi Arabia: USD 16.65 million in 2025 with 31% share, projected to hit USD 33.63 million by 2034 at 8.12% CAGR, supported by radiotherapy adoption.
• South Africa: USD 11.26 million in 2025 with 21% share, reaching USD 22.72 million by 2034 at 8.13% CAGR, driven by oncology growth.
• Egypt: USD 9.1 million in 2025 with 17% share, forecasted to reach USD 18.34 million by 2034 at 8.12% CAGR, reflecting hospital adoption.
• Nigeria: USD 8.05 million in 2025 with 15% share, projected to hit USD 16.23 million by 2034 at 8.11% CAGR, supporting diagnostic care.
• UAE: USD 7.26 million in 2025 with 13% share, expected to reach USD 14.56 million by 2034 at 8.12% CAGR, supported by advanced healthcare expansion.

List of Top Medical Radioisotopes Companies

• Nordion
• NTP Radioisotopes
• China National Nuclear Corporation
• NRG
• Eckert & Ziegler Strahlen
• Polatom
• IRE
• Rosatom
• ANSTO

Top Two Companies With Highest Share

• Nordion accounted for 20% of global cobalt-60 supply, producing isotopes for over 1 million cancer treatments annually. China National Nuclear Corporation supplied 25% of Tc-99m isotopes globally, supporting over 10 million diagnostic scans worldwide.

Investment Analysis and Opportunities

Investment in the Medical Radioisotopes Market exceeded USD 2 billion equivalent in 2024, with 40% directed at new cyclotron facilities. Asia-Pacific attracted the highest investments, with China building 6 new isotope plants and India commissioning 2. North America invested in expanding 3 cyclotron centers, adding capacity for 1 million Tc-99m doses annually. Europe invested in isotope waste treatment facilities, with 200 million allocated to new disposal systems. Africa received new investments in diagnostic centers, with 10 hospitals upgraded for nuclear medicine in 2024. The opportunities lie in diversifying isotope supply, expanding PET imaging, and increasing regional self-sufficiency in isotope production.

New Product Development

The Medical Radioisotopes Market is witnessing accelerated product innovation. In 2024, more than 20 new isotope-based diagnostic kits were launched, including Tc-99m radiopharmaceuticals for cardiology and oncology. Over 5 new cobalt-60 radiotherapy machines were approved, delivering 15% greater treatment precision. Cyclotron-produced Tc-99m gained traction, with pilot-scale production meeting 5% of North American demand. Iodine-125 brachytherapy seeds saw expanded use in prostate cancer treatment, with more than 50,000 procedures performed globally. Artificial intelligence integration in imaging enabled 10% faster interpretation of isotope scans. Companies also developed waste-minimization products, cutting radioactive waste volumes by 12% compared to 2023.

Five Recent Developments

• China National Nuclear Corporation added 6 new isotope production plants in 2024, increasing global Tc-99m supply by 15%.
• Nordion expanded cobalt-60 production capacity in 2023, raising global treatment coverage to 1.2 million patients.
• ANSTO launched a new Tc-99m radiopharmaceutical in 2024, serving over 100,000 patient scans in Australia.
• Rosatom established a medical isotope export hub in 2023, expanding supply to 12 new countries.
• NRG upgraded its Petten reactor in 2024, increasing isotope output by 10% annually.

Report Coverage of Medical Radioisotopes Market

The Medical Radioisotopes Market Report provides a detailed analysis of type, application, and regional segmentation. Tc-99m dominates with 80% global diagnostic share, cobalt-60 accounts for over 500,000 radiotherapy treatments annually, and iodine isotopes treat 1.2 million thyroid cases. The market covers applications in nuclear therapy, diagnosis, and radioactive equipment sources. North America leads with 42% share, followed by Europe at 28%, Asia-Pacific at 23%, and Middle East & Africa at 7%. The report covers leading companies such as Nordion, NTP, CNNC, and Rosatom, with profiles of production volumes, geographic presence, and product innovations. Investment analysis highlights over USD 2 billion invested in 2024 for isotope facilities and waste management. The scope includes detailed Medical Radioisotopes Market Trends, Medical Radioisotopes Market Forecast, Medical Radioisotopes Market Insights, and Medical Radioisotopes Market Opportunities for B2B stakeholders.

Medical Radioisotopes Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 834.59 Million in 2026
Market Size Value By	USD 1685.26 Million by 2035
Growth Rate	CAGR of 8.12% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Tc-99m Cobalt-60 Iodine Radioisotopes By Application : Nuclear Therapy Equipment Radioactive Source Diagnosis Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample